Visfatin and Resistin Serum Levels in Normal-Weight and Obese Women With Polycystic Ovary Syndrome

Authors Information
Article Notes and Dates
To Cite : Farshchian F, Ramezani Tehrani F, Amirrasouli H, Rahimi Pour H, Hedayati M, et al. Visfatin and Resistin Serum Levels in Normal-Weight and Obese Women With Polycystic Ovary Syndrome, Int J Endocrinol Metab. 2014 ;12(3):e15503. doi: 10.5812/ijem.15503.
Copyright: Copyright © 2014, International Journal of Endocrinology and Metabolism. .
Abstract
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011; 7(4): 219-31[DOI][PubMed]
  • 2. Sun L, Hu W, Liu Q, Hao Q, Sun B, Zhang Q, et al. Metabonomics reveals plasma metabolic changes and inflammatory marker in polycystic ovary syndrome patients. J Proteome Res. 2012; 11(5): 2937-46[DOI][PubMed]
  • 3. Zhao Y, Fu L, Li R, Wang LN, Yang Y, Liu NN, et al. Metabolic profiles characterizing different phenotypes of polycystic ovary syndrome: plasma metabolomics analysis. BMC Med. 2012; 10: 153[DOI][PubMed]
  • 4. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012; 33(6): 981-1030[DOI][PubMed]
  • 5. Lim SS, Davies MJ, Norman RJ, Moran LJ. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2012; 18(6): 618-37[DOI][PubMed]
  • 6. Brewer CJ, Balen AH. The adverse effects of obesity on conception and implantation. Reproduction. 2010; 140(3): 347-64[DOI][PubMed]
  • 7. Chen X, Jia X, Qiao J, Guan Y, Kang J. Adipokines in reproductive function: a link between obesity and polycystic ovary syndrome. J Mol Endocrinol. 2013; 50(2)-37[DOI][PubMed]
  • 8. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. Nature. 2001; 409(6818): 307-12[DOI][PubMed]
  • 9. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006; 6(10): 772-83[DOI][PubMed]
  • 10. Bohler H Jr, Mokshagundam S, Winters SJ. Adipose tissue and reproduction in women. Fertil Steril. 2010; 94(3): 795-825[DOI][PubMed]
  • 11. Schwartz DR, Lazar MA. Human resistin: found in translation from mouse to man. Trends Endocrinol Metab. 2011; 22(7): 259-65[DOI][PubMed]
  • 12. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol. 1994; 14(2): 1431-7[PubMed]
  • 13. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005; 307(5708): 426-30[DOI][PubMed]
  • 14. Hug C, Lodish HF. Medicine. Visfatin: a new adipokine. Science. 2005; 307(5708): 366-7[DOI][PubMed]
  • 15. Jacques C, Holzenberger M, Mladenovic Z, Salvat C, Pecchi E, Berenbaum F, et al. Proinflammatory actions of visfatin/nicotinamide phosphoribosyltransferase (Nampt) involve regulation of insulin signaling pathway and Nampt enzymatic activity. J Biol Chem. 2012; 287(18): 15100-8[DOI][PubMed]
  • 16. Chang YC, Chang TJ, Lee WJ, Chuang LM. The relationship of visfatin/pre-B-cell colony-enhancing factor/nicotinamide phosphoribosyltransferase in adipose tissue with inflammation, insulin resistance, and plasma lipids. Metabolism. 2010; 59(1): 93-9[DOI][PubMed]
  • 17. Choi KM, Kim JH, Cho GJ, Baik SH, Park HS, Kim SM. Effect of exercise training on plasma visfatin and eotaxin levels. Eur J Endocrinol. 2007; 157(4): 437-42[DOI][PubMed]
  • 18. Filippatos TD, Derdemezis CS, Kiortsis DN, Tselepis AD, Elisaf MS. Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome. J Endocrinol Invest. 2007; 30(4): 323-6[PubMed]
  • 19. Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab. 2006; 91(4): 1578-81[DOI][PubMed]
  • 20. Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R, et al. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab. 2006; 91(8): 3165-70[DOI][PubMed]
  • 21. Panidis D, Farmakiotis D, Rousso D, Katsikis I, Delkos D, Piouka A, et al. Plasma visfatin levels in normal weight women with polycystic ovary syndrome. Eur J Intern Med. 2008; 19(6): 406-12[DOI][PubMed]
  • 22. Carmina E, Bucchieri S, Mansueto P, Rini G, Ferin M, Lobo RA. Circulating levels of adipose products and differences in fat distribution in the ovulatory and anovulatory phenotypes of polycystic ovary syndrome. Fertil Steril. 2009; 91(4 Suppl): 1332-5[DOI][PubMed]
  • 23. Chan TF, Chen YL, Chen HH, Lee CH, Jong SB, Tsai EM. Increased plasma visfatin concentrations in women with polycystic ovary syndrome. Fertil Steril. 2007; 88(2): 401-5[DOI][PubMed]
  • 24. Kowalska I, Straczkowski M, Nikolajuk A, Adamska A, Karczewska-Kupczewska M, Otziomek E, et al. Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Hum Reprod. 2007; 22(7): 1824-9[DOI][PubMed]
  • 25. Ozkaya M, Cakal E, Ustun Y, Engin-Ustun Y. Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome. Fertil Steril. 2010; 93(3): 880-4[DOI][PubMed]
  • 26. Plati E, Kouskouni E, Malamitsi-Puchner A, Boutsikou M, Kaparos G, Baka S. Visfatin and leptin levels in women with polycystic ovaries undergoing ovarian stimulation. Fertil Steril. 2010; 94(4): 1451-6[DOI][PubMed]
  • 27. Seow KM, Hwang JL, Wang PH, Ho LT, Juan CC. Expression of visfatin mRNA in peripheral blood mononuclear cells is not correlated with visfatin mRNA in omental adipose tissue in women with polycystic ovary syndrome. Hum Reprod. 2011; 26(10): 2869-73[DOI][PubMed]
  • 28. Tan BK, Chen J, Digby JE, Keay SD, Kennedy CR, Randeva HS. Increased visfatin messenger ribonucleic acid and protein levels in adipose tissue and adipocytes in women with polycystic ovary syndrome: parallel increase in plasma visfatin. J Clin Endocrinol Metab. 2006; 91(12): 5022-8[DOI][PubMed]
  • 29. Guducu N, Isci H, Gormus U, Yigiter AB, Dunder I. Serum visfatin levels in women with polycystic ovary syndrome. Gynecol Endocrinol. 2012; 28(8): 619-23[DOI][PubMed]
  • 30. Lajunen TK, Purhonen AK, Haapea M, Ruokonen A, Puukka K, Hartikainen AL, et al. Full-length visfatin levels are associated with inflammation in women with polycystic ovary syndrome. Eur J Clin Invest. 2012; 42(3): 321-8[DOI][PubMed]
  • 31. Olszanecka-Glinianowicz M, Madej P, Zdun D, Bozentowicz-Wikarek M, Sikora J, Chudek J, et al. Are plasma levels of visfatin and retinol-binding protein 4 (RBP4) associated with body mass, metabolic and hormonal disturbances in women with polycystic ovary syndrome? Eur J Obstet Gynecol Reprod Biol. 2012; 162(1): 55-61[DOI][PubMed]
  • 32. Munir I, Yen HW, Baruth T, Tarkowski R, Azziz R, Magoffin DA, et al. Resistin stimulation of 17alpha-hydroxylase activity in ovarian theca cells in vitro: relevance to polycystic ovary syndrome. J Clin Endocrinol Metab. 2005; 90(8): 4852-7[DOI][PubMed]
  • 33. Escobar-Morreale HF, Villuendas G, Botella-Carretero JI, Alvarez-Blasco F, Sanchon R, Luque-Ramirez M, et al. Adiponectin and resistin in PCOS: a clinical, biochemical and molecular genetic study. Hum Reprod. 2006; 21(9): 2257-65[DOI][PubMed]
  • 34. Olszanecka-Glinianowicz M, Kuglin D, Dabkowska-Huc A, Skalba P. Serum adiponectin and resistin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2011; 154(1): 51-6[DOI][PubMed]
  • 35. Panidis D, Koliakos G, Kourtis A, Farmakiotis D, Mouslech T, Rousso D. Serum resistin levels in women with polycystic ovary syndrome. Fertil Steril. 2004; 81(2): 361-6[DOI][PubMed]
  • 36. Seow KM, Juan CC, Ho LT, Hsu YP, Lin YH, Huang LW, et al. Adipocyte resistin mRNA levels are down-regulated by laparoscopic ovarian electrocautery in both obese and lean women with polycystic ovary syndrome. Hum Reprod. 2007; 22(4): 1100-6[DOI][PubMed]
  • 37. Seow KM, Juan CC, Hsu YP, Ho LT, Wang YY, Hwang JL. Serum and follicular resistin levels in women with polycystic ovarian syndrome during IVF-stimulated cycles. Hum Reprod. 2005; 20(1): 117-21[DOI][PubMed]
  • 38. Zhang J, Zhou L, Tang L, Xu L. The plasma level and gene expression of resistin in polycystic ovary syndrome. Gynecol Endocrinol. 2011; 27(12): 982-7[DOI][PubMed]
  • 39. Urbanek M, Du Y, Silander K, Collins FS, Steppan CM, Strauss JF 3rd, et al. Variation in resistin gene promoter not associated with polycystic ovary syndrome. Diabetes. 2003; 52(1): 214-7[PubMed]
  • 40. Xita N, Georgiou I, Tsatsoulis A, Kourtis A, Kukuvitis A, Panidis D. A polymorphism in the resistin gene promoter is associated with body mass index in women with polycystic ovary syndrome. Fertil Steril. 2004; 82(5): 1466-7[DOI][PubMed]
  • 41. Majuri A, Santaniemi M, Rautio K, Kunnari A, Vartiainen J, Ruokonen A, et al. Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study. Eur J Endocrinol. 2007; 156(2): 263-9[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiaion Alert via Google Reader

Cited By:

International Journal of Endocrinology and Metabolism accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check